Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Kenya
Research question
- What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of lymphatic filariasis has been reduced so that triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) can be stopped with little risk of resurgence of transmission?
- Can the use of a tailored social mobilization package be used to strengthen community and health system participation and achieve >80% coverage for IDA in Kenya?
Study sites
Regional study site, Kenya
In progress
Implementation partner(s)
Sample(s)
Total sample size: 7500 Human
Notes
This is a two-part study.
Listen to the audio publication about this research from the Task Force for Global Health, Join a Research Trip to Lamu, Kenya.